Tag Archives: vrtx

Vertex Not A Good Fit For Gilead, Says Piper Jaffray

Piper Jaffray placed its bets in the biotech M&A speculation game Friday, saying that Gilead Sciences (GILD) could acquire Incyte (INCY) or Bristol-Myers Squibb (BMY) but probably wouldn’t be as interested in Vertex Pharmaceuticals (VRTX). In a report reviewing M&A in the biopharma sector, analyst Joshua Schimmer wrote that “the best fit for Gilead is a derisked, later-stage asset or collection of assets, particularly in light of the company’s

Vertex’s Orkambi Approved For CF, Prices On High Side

The FDA on Thursday afternoon approved Vertex Pharmaceuticals’ (VRTX) potential blockbuster cystic-fibrosis drug Orkambi, which the company priced at $259,000 per year, on the high side of investors’ expectations. The agency gave the nod to Orkambi, a combination of ivacaftor (which Vertex markets separately as Kalydeco) and lumacaftor, a booster that makes the drug effective in treating a much larger population than ivacaftor alone. The FDA

Vertex CF Drug Orkambi Wins FDA Advisory Panel Vote

An advisory panel to the Food and Drug Administration voted 12-1 in favor of approving Vertex Pharmaceuticals’ (VRTX) cystic-fibrosis drug Orkambi Tuesday afternoon. The FDA has until July 5 to decide on approval, but it usually follows the recommendations of its panels. So much buzz surrounded the event that trading in Vertex stock was halted all day Tuesday while the panel debated the issues. Orkambi is a combination of Vertex’s drug Kalydeco,